Warfarin Therapy: Evolving Strategies in Anticoagulation

Warfarin Therapy: Evolving Strategies in Anticoagulation

Jon D. Horton

Warfarin is the oral anticoagulant most frequently used to control and prevent thromboembolic disorders. Proscribing the dose that both avoids hemorrhagic complications and achieves sufficient suppression of thrombosis requires a thorough understanding of the drug’s unique pharmacology. Warfarin has a complex dose-response relationship that makes safe and effective use a challenge. For most indications, the dose is adjusted to maintain the patient’s International Normalized Ratio (INR) at 2 to 3. Because of the delay in factor II (prothrombin) suppression, heparin is administered concurrently for four to five days to prevent thrombus propagation. Loading doses of warfarin are not warranted and may result in bleeding complications. Interactions with other drugs must be considered, and therapy in elderly patients requires careful management. Current dosing recommendations are reviewed, and practical guidelines for the optimal use of warfarin are provided.

Warfarin (Coumadin) is the most frequently prescribed oral anticoagulant, the fourth most prescribed cardiovascular agent and the overall eleventh most prescribed drug in the United States,[1] with annual sales of approximately $500 million.[2] Nonetheless, in 1995 the Agency for Healthcare Policy and Research (AHCPR)[3] reported that warfarin is greatly underutilized for stroke prevention. The AHCPR noted that physicians are reluctant to prescribe warfarin, in part because they are not familiar with techniques for administering the drug safely and fear that the drug will cause bleeding. Patients treated with warfarin do require close monitoring to avoid bleeding, but it has been shown that the drug prevents 20 strokes for every bleeding episode that it causes.[3]

Even though four decades have passed since warfarin was first used to prevent thromboembolic disease, studies continue to discover and refine techniques that make therapy with this agent safer and more effective. Because warfarin has a complex dose-response relationship, family physicians need to understand the drug’s pharmacology. This article presents the rationale for published dosing recommendations and suggests practical guidelines for the use of warfarin therapy.

Goals of Anticoagulation

The goal of anticoagulant therapy is to administer the lowest possible dose of anticoagulant to prevent clot formation or expansion. The required degree of anticoagulation continues to evolve as studies provide more information about the efficacy and safety of lower doses. Current therapeutic goals for various disease states are summarized in Table 1.[4-9]

TABLE 1

Recommended Therapeutic Goals for Oral Anticoagulation

Indication INR

Prophylaxis of venous thrombosis 2 to 3

for high-risk surgery

Treatment of venous thrombosis

First episode 2 to 3

High risk of recurrent thrombosis 2 to 3

Thrombosis associated with 3 to 4

antiphospholipid antibody

Treatment of pulmonary embolism

First episode 2 to 3

High risk of recurrent embolism 2 to 3

Prevention of systemic embolism

Tissue heart valves 2 to 3

Acute myocardial infarction 2 to 3

(to prevent systemic

embolism)([dagger])

Valvular heart disease (after 2 to 3

thrombotic event or if the left

atrium is greater than 5.5 cm)

Atrial fibrillation

Chronic or intermittent 2 to 3

Cardioversion 2 to 3

Prosthetic heart valves

Aortic position

Mechanical 2.5 to 3.5([double dagger])

Bioprosthetic 2 to 3

Mitral position

Mechanical 2.5 to 3.5([double dagger])

Bioprosthetic 2 to 3

Indication Duration

Prophylaxis of venous thrombosis Clinical judgment

for high-risk surgery

Treatment of venous thrombosis

First episode 3 to 6 months(*)

High risk of recurrent thrombosis Lifelong

Thrombosis associated with Lifelong

antiphospholipid antibody

Treatment of pulmonary embolism

First episode 3 to 6 months

High risk of recurrent embolism Lifelong

Prevention of systemic embolism

Tissue heart valves 3 months

Acute myocardial infarction Clinical judgment

(to prevent systemic

embolism)([dagger])

Valvular heart disease (after Lifelong

thrombotic event or if the left

atrium is greater than 5.5 cm)

Atrial fibrillation

Chronic or intermittent Lifelong

Cardioversion 3 weeks before and 4

weeks after atrial

fibrillation if normal sinus

rhythm is maintained

Prosthetic heart valves

Aortic position

Mechanical Lifelong

Bioprosthetic Clinical judgment (3 months

optional)

Mitral position

Mechanical Lifelong

Bioprosthetic 3 months

INR = International Normalized Ratio.

(*)–One study[6] suggested that 4 weeks may be an adequate duration of oral anticoagulant therapy in patients without continuing risk factors.

([dagger])–If oral anticoagulant therapy is elected to prevent recurrent myocardial infarction, an INR of 2.5 to 3.5 is recommended.

([double dagger])–Depending on the type of mechanical valve (i.e., caged ball or caged disk) and the valve position (mitral), some patients may benefit from INRs in the upper end of the range.

Information derived from references 4 through 9.

By using the lowest possible required dose of warfarin, the physician can minimize the risk of bleeding while providing the benefits of anticoagulation. To achieve this goal, the physician must have a working knowledge of the pharmacologic, pharmacokinetic and pharmacodynamic properties of warfarin.

Pharmacology

Warfarin is an antagonist of vitamin K, a necessary element in the synthesis of clotting factors II, VII, IX and X, as well as the naturally occurring endogenous anticoagulant proteins C and S. These factors and proteins are biologically inactive without the carboxylation of certain glutamic acid residues. This carboxylation process requires oxidized vitamin K as a cofactor and occurs primarily in the liver. Antagonism of vitamin K or a deficiency of this vitamin reduces the rate at which these factors and proteins are produced, thereby creating a state of anticoagulation.

Therapeutic doses of warfarin reduce the production of functional vitamin K-dependent clotting factors by approximately 30 to 50 percent. A concomitant reduction in the carboxylation of secreted clotting factors yields a 10 to 40 percent decrease in the biologic activity of the clotting factors. As a result, the coagulation system becomes functionally deficient.[10]

Pharmacokinetics

A knowledge of the pharmacokinetics of warfarin is helpful in understanding the initial response to therapy. Warfarin can be detected in the plasma one hour after oral administration, and peak concentrations occur in two to eight hours.[10]

Warfarin is a racemic mixture of stereo isomers, which are 99 percent bound to albumin.[11] The drug is metabolized in the liver and kidneys, with the subsequent production of inactive metabolites that are excreted in the urine and stool.[10]

The half-life of racemic warfarin ranges from 20 to 60 hours. The mean plasma half-life is approximately 40 hours, and the duration of effect is two to five days.[10] Thus, the maximum effect of a dose occurs up to 48 hours after administration, and the effect lingers for the next five days.

Pharmacodynamics and Dosing Considerations

Anticoagulant Activity. The anticoagulant activity of warfarin depends on the clearance of functional clotting factors from the systemic circulation after administration of the dose. The clearance of these dotting factors is determined by their half-lives. The earliest changes in the International Normalized Ratio (INR) are typically noted 24 to 36 hours after a dose of warfarin is administered. These changes are due to the clearance of functional factor VII, which is the vitamin K-dependent clotting factor with the shortest half-life (six hours). However, the early changes in the INR are deceptive because they do not actually affect the body’s physiologic ability to halt clot expansion or form new thromboses.[4]

Antithrombotic Effect. The antithrombotic effect of warfarin, or the inability to expand or form clots, is not present until approximately the fifth day of therapy. This effect depends on the clearance of functional factor II (prothrombin), which has a half-life of approximately 50 hours in patients with normal hepatic function.

The difference between the antithrombotic and anticoagulant effects of warfarin need to be understood and applied in clinical practice. Because antithrombotic effect depends on the clearance of prothrombin (which may take up to five days), loading doses of warfarin are of limited value.[4, 12] Because warfarin has a long half-life, increases in the INR may not be noted for 24 to 36 hours after administration of the first dose, and maximum anticoagulant effect may not be achieved for 72 to 96 hours.[4]

Loading doses of warfarin (i.e., 10 mg or more per day) may increase the patient’s risk of bleeding episodes early in therapy by eliminating or severely reducing the production of functional factor VII. The administration of loading doses is a possible source of prolonged hospitalization secondary to dramatic rises in INR that necessitate increased monitoring. Administration of loading doses has also been hypothesized to potentiate a hypocoagulable state because of severe depletion of protein C. The practice of using loading doses should be abandoned because it has no effect on the inhibition of thrombosis.[4]

A potential paradoxic consequence of loading doses is the development of a hypercoagulable state because of a precipitous reduction in the concentration of protein C (approximate half-life of eight hours) during the first 36 hours of warfarin therapy.[12] Thus, loading doses theoretically may cause clot formation and/or expansion by limiting the production of proteins C and S, which have shorter half-lives than prothrombin. Consequently, the concurrent use of heparin is extremely important.

The initial dose of warfarin should approximate the chronic maintenance dose that is anticipated. In most patients, the average maintenance dose is 4 to 6 mg per day. Dose has an inverse relation with age. In patients 50 years old, the average daily dose is 6.3 mg; in patients 70 years old, the average daily dose is 3.6 mg.[13]

Drug interactions (discussed in detail in another section) need to be considered when warfarin therapy is initiated. Other factors include the patient’s nutritional status and gender. Patients who are malnourished should receive lower doses of warfarin because they probably have low vitamin K intake and decreased serum albumin concentrations. Women generally require lower doses than men.

Patients at highest risk for complications should probably be given a smaller initial dose (2 to 4 mg per day). This dose is then titrated to the lower end of a given therapeutic range, depending on the indication. For example, the goal may be an INR of 2 to 2.5 in a patient with a history of bleeding, chronic atrial fibrillation and no additional risk factors for thrombosis.

Current recommendations for the initiation of warfarin therapy differ based on the urgency for achieving an anticoagulant effect. While warfarin is being initiated, patients who require rapid anticoagulation should also be given unfractionated heparin or low molecular-weight heparin intravenously or subcutaneously in doses appropriate for the given indication.[4]

Heparin and warfarin therapies should overlap for approximately four to five days. The presence of a therapeutic INR does not confer protection from clot formation and expansion during the first few days of warfarin therapy because of the delay in the therapeutic inhibition of prothrombin.

Patients who rapidly achieve a therapeutic INR may metabolize warfarin slowly and thus may require lower maintenance doses. The opposite holds for patients who tend to respond slowly to warfarin.[13]

A small decrease in the INR is expected to occur with the discontinuation of unfractionated heparin therapy.[14] (A drop of 0.3 to 0.8 in the INR has been noted by the authors of this article.)

Patients who require nonurgent anticoagulation, such as those with stable chronic atrial fibrillation, can be started on warfarin as outpatients, without the concomitant administration of heparin.[4]

The goal of maintenance therapy is to achieve a regimen that is simple yet provides therapeutic anticoagulation. Currently, many physicians use drug regimens that appear simple but require differing tablet strengths. These regimens can be confusing to elderly patients who are taking several other medications concurrently and who may confuse tablet colors and strengths.

Effective anticoagulation can be achieved using a single tablet strength and alternating fractions or multiples of that tablet on given days of the week rather than on odd or even days.[15] As needed, doses can be easily changed by looking at the cumulative weekly dosage and adding or subtracting 10 to 20 percent evenly over the week[15, 16] (Figure 1). This approach is possible because of warfarin’s long half-life. Ii is a safe and effective way to provide sufficient anticoagulation. Algorithms for establishing a percentage change in the weekly dosage to achieve an INR of 2 to 3 or 2.5 to 3.5 are presented in Figures 2 and 3, respectively.[17]

Warfarin Dosing Adjustment Using One Tablet Strength (5 mg)

Sunday Monday Tuesday Wednesday Thursday

1 tablet 0.5 tablet 1 tablet 0.5 tablet 1 tablet

1 tablet 0.5 tablet 1 tablet 1 tablet 1 tablet

1 tablet 0.5 mg 1 tablet 1 tablet 1 tablet

1 tablet 1 tablet 1 tablet 1 tablet 1 tablet

1 tablet 1.5 tablets 1 tablet 1 tablet 1 tablet

1 tablet 1.5 tablets 1 tablet 1 tablet 1 tablet

1 tablet 1.5 tablets 1 tablet 1.5 tablets 1 tablet

Total Approximate

Friday Saturday weekly dosage adjustment (%)

0.5 tablet 1 tablet 27.5 mg -20

0.5 tablet 1 tablet 30 mg -15

1 tablet 1 tablet 32.5 mg -5

1 tablet 1 tablet 35 mg 0

1 tablet 1 tablet 37.5 mg +5

1.5 tablets 1 tablet 40 mg +15

1.5 tablets 1 tablet 42.5 mg +20

FIGURE 1. Warfarin dosing adjustments based on the algorithms presented in Figures 2 and 3. Only one tablet strength (5 mg) is used. Fractions or multiples of the tablet can be used for different doses, or alternative doses can be given based on the day of the week. Dose adjustments should be made based on the total weekly dosage, with increases or decreases of 10 to 20 percent spread out over the week.

Questions have recently been raised about the use of generic warfarin products.[18] The cost savings of changing to generic products was investigated at Boston City Hospital during the late 1980s.[19] The study found that patients who used Coumadin exclusively remained within the goal INR 68 percent of the time, whereas patients who used generic warfarin maintained goal INR only 39 percent of the time. Compared with the brand drug-treated patients, the 15 patients who switched products had more dosage adjustments, one hospitalization for excessive anticoagulation and one emergency department visit for epistaxis. None of the patients maintained on the brand drug required hospitalization or emergency medical care.

Generic warfarin products and Coumadin have small pharmacokinetic differences in time to peak concentration, area under the curve, absorption rate constants, half-absorption time and tablet content uniformity.[18] Therefore, increased monitoring may be prudent when a patient is switched from the brand drug to generic warfarin.

As noted in the Boston City Hospital study,[19] the slight cost advantage of the generic product may be outweighed by increased monitoring costs, increased physician time and a possibly greater incidence of adverse events. If a generic warfarin product is started and then used exclusively in a patient, it is likely to be as safe as the brand drug.

Monitoring

The prothrombin time (PT) is the primary assay used in monitoring warfarin therapy. The prolongation of PT depends on reductions in three of the vitamin K-dependent clotting factors (II, VII and IX). Changes in the PT noted in the first few days of warfarin therapy are primarily due to reductions in factors VII and IX, which have the shortest half-lives (six and 24 hours, respectively).

The early changes in PT vary based on the responsiveness of the particular thromboplastin that a laboratory uses to perform the PT test.[4] The International Sensitivity Index is used to measure and compare the variability in thromboplastin responsiveness. Because of the variations in thromboplastin sensitivity and the different ways of reporting PT, information about patients treated with oral anticoagulants was not interchangeable among laboratories until 1982, when the World Health Organization Expert Committee on Biologic Standardization developed the INR.[20]

When a patient is started on an oral anticoagulant, INR monitoring should be performed on a daily basis until the INR is within the therapeutic range for at least two consecutive days. Then INR monitoring should be performed two to three times a week for one to two weeks. If the patient remains stable, this interval can be widened to a monitoring frequency of once every four to six weeks. If dosage adjustments are necessary, INR monitoring should be performed more often until a new state of stability is achieved.

Unexpected fluctuations of the INR in an otherwise stable patient should be investigated. Often, it is possible to identify one or more causes, such as change in diet, poor compliance, undisclosed drug use, alcohol consumption and/or self-medication. If none of these causes can be identified, laboratory error should be considered. When no cause for INR fluctuations can be determined, weekly dosage adjustment should be tried. The reduction or withholding of a single dose or an increase in that day’s dose is often sufficient to restore a therapeutic INR in a patient who is otherwise medically stable.

Hemorrhagic Complications

The most common complication of warfarin therapy is bleeding, which occurs in 6 to 39 percent of recipients annually.[4,21] The incidence of bleeding is directly related to the intensity of anticoagulation. With the reductions in anticoagulation intensity that have evolved over the past 20 years, the incidence of hemorrhagic complications has decreased dramatically.

In patients receiving warfarin therapy, the median annual rate of major bleeding ranges from 0.9 to 2.7 percent, and the median annual rate of fatal bleeding ranges from 0.07 to 0.7 percent. The incidence of complications varies within the ranges, depending on the clinical indication and the intensity of anticoagulation. Intracranial hemorrhage accounts for approximately 2 percent of the reported hemorrhagic complications of warfarin therapy and is associated with a mortality rate of 10 to 68 percent.[22]

Patient characteristics associated with a major risk of hemorrhage have been identified in a number of randomized studies (Table 2).[4, 20, 23-27] Bleeding that occurs with an INR of less than 3 is often associated with an underlying occult gastrointestinal or renal lesion.[4]

TABLE 2 Risk Factors for Hemorrhagic Complications of Anticoagulation Therapy

Age greater than 65 years[23]

Age greater than 75 years with concomitant atrial

fibrillation (intracranial hemorrhage)[24, 25]

History of gastrointestinal bleeding[20]

Comorbid disease states[26]

Hypertension[20, 27]

Cerebrovascular disease[20]

Serious heart disease[4,20]

Renal insufficiency[20]

Information from references 4, 20, and 23 through 27.

If bleeding occurs during warfarin therapy, the physician should immediately consider the severity of bleeding, the intensity of anticoagulation at the time of the bleeding episode and whether the patient has completed most of the prescribed course of therapy. Recommendations for the reversal of high INR values in patients with or without bleeding are summarized in Figure 4.[4]

[Figure 4 ILLUSTRATION OMITTED]

Warfarin resistance is common after the administration of large doses of vitamin K. If anticoagulation therapy must be continued, heparin therapy should be initiated until the effects of vitamin K have been reversed and the patient is again responsive to warfarin.

Anticoagulation Therapy in the Elderly

One of the physician’s most difficult tasks is to decide whether the risk of anticoagulation outweighs the potential benefit of warfarin therapy in an elderly patient. One study[28] found that the risk of intracranial hemorrhage among the elderly is highest in patients with poor control (large variations in INR), patients receiving high-intensity therapy (INR greater than 4) and patients older than 80 years. Data from the Stroke Prevention in Atrial Fibrillation (SPAF II) trial[29] suggest that the safety of anticoagulation in the elderly can be maximized through careful monitoring and maintenance of an INR between 2 and 3.

Another recent study[30] investigated the incidence of ischemic stroke in elderly patients with atrial fibrillation who were receiving anticoagulant therapy. This study found that subtherapeutic INRs (i.e., those below 2) have associated risks of thrombotic events. For example, the relative risk of ischemic stroke is 3.3 times higher (95 percent confidence interval 2.4 to 4.6) in a patient with an INR of 1.5 than in a patient with an INR of 2. The study findings suggest that tighter control of therapy at an INR range of 2 to 3 is superior to the use of lower levels of anticoagulation.

The SPAF III study[31] compared the effects of combined fixed-dose warfarin and aspirin (goal INR of 1.2 to 1.5) with the effects of warfarin titrated to an INR of 2 to 3. The study was discontinued after a mean follow-up period of 1.1 years because of the occurrence of significantly fewer events in the adjusted-dose warfarin group (7.9 percent per year) compared with the warfarin and aspirin group (1.9 percent per year). This reduction in events was associated with similar major bleeding rates (2.1 percent for adjusted-dose warfarin and 2.4 percent for combination therapy). Interestingly, in the adjusted-dose group, the INR was greater than 3 in seven of the 12 major bleeding events.

Drug Interactions

In determining whether to treat a patient with warfarin, one of the major concerns is the risk of potential drug interactions (Table 3)[32,33] Drug interactions of varying severity have been identified with warfarin therapy. In most instances, the interacting drugs either inhibit or induce warfarin metabolism. These types of interactions are easily managed when the medications are for the treatment of chronic diseases. In such circumstances, close INR monitoring is required during the initiation or discontinuation of the medications.

TABLE 3

Selected Warfarin-Drug Interactions

Characteristics of interaction

Drug Severity Onset Evidence

Acetaminophen Minor Delayed Poor

(Tylenol)

Allopurinol Moderate Delayed Poor

(Zyloprim)

Amiodarone Moderate Delayed Excellent

(Cordarone)

Antifungal Major Delayed Good

agents

Antithyroid Moderate Delayed Fair

drugs

Barbiturates Major Delayed Excellent

Binding resins Moderate Delayed Good

Carbamazepine Moderate Delayed Fair

(Tegretol)

Cephalosporins Moderate Delayed Poor

Cimetidine Moderate Delayed Excellent

(Tagamet)

Contraceptives, Minor Delayed Poor

oral

Corticosteroids Moderate Delayed Poor

Danazol Major Delayed Good

(Danocrine)

Diflunisal Moderate Delayed Fair

(Dolobid)

Disulfiram Moderate Delayed Fair

(Antabuse)

Ethanol Moderate Delayed Excellent

Fluvoxamine Moderate Delayed Fair

(Luvox)

Heparin Moderate Rapid Good

HMG CoA Moderate Delayed Poor

reductase

inhibitors

Isoniazid Moderate Delayed Poor

(Laniazid)

Metronidazole Moderate Delayed Fair

(Flagyl)

Nalidixic acid Moderate Delayed Poor

(NegGram)

NSAIDs Moderate Delayed Fair

Paroxetine Moderate Delayed Poor

(Paxil)

Penicillins Moderate Delayed Fair

Phenytoin Major Delayed Fair

(Dilantin)

Propafenone Moderate Delayed Fair

(Rythmol)

Quinolones Moderate Delayed Poor

Rifampin Moderate Delayed Poor

(Rifadin)

and rifabutin

(Mycobutin)

Salicylates Major Delayed Excellent

Sulfinpyrazone Moderate Delayed Excellent

(Anturane)

Thyroid Moderate Delayed Excellent

hormones

Ticlopidine Moderate Delayed Poor

(Ticlid)

Trimethoprim- Major Delayed Excellent

sulfamethoxazole

(Bactrim)

Vitamin E Moderate Delayed Fair

Vitamin K Moderate Delayed Excellent

Drug Mechanism

Acetaminophen Inhibits warfarin metabolism

(Tylenol)

Allopurinol Unknown

(Zyloprim)

Amiodarone Decreases warfarin metabolism within

(Cordarone) a week of coadministration; effect

may persist for 1 to 3 months after

discontinuation of amiodarone

May induce hypothyroidism or

hyperthyroidism

Antifungal Fluconazole (Diflucan), ketoconazole

agents (Nizoral) and miconazole (Monistat)

decrease warfarin metabolism

Antithyroid Hyperthyroidism results in metabolism

drugs of vitamin K clotting factors and

increased sensitivity to oral

anticoagulants

Barbiturates Increase warfarin metabolism and

frequently reduce

hypoprothrombinemic effect of

warfarin

Binding resins Decrease absorption and may interrupt

enterohepatic recirculation

of warfarin

Carbamazepine Increases warfarin metabolism

(Tegretol)

Cephalosporins Methylthiotetrazole ring in cefoperazone

(Cefobid), cefamandole (Mandol),

cefotetan (Cefotan) and cefmetazole

(Zefazone) inhibits production of

vitamin K-dependent clotting factors

Cimetidine Inhibits warfarin metabolism;

(Tagamet) predominantly affects R isomer

Contraceptives, May increase clotting factor synthesis

oral May inhibit oxidative metabolism

Corticosteroids Produce hypercoagulability

May have ulcerogenic effects

Danazol May increase endogenous anticoagulants

(Danocrine)

Diflunisal Displaces warfarin from protein binding,

(Dolobid) inhibits platelet aggregation, causes

gastric erosions

Disulfiram Inhibits warfarin metabolism

(Antabuse)

Ethanol Acute ethanol use may inhibit

anticoagulant metabolism,

Chronic ethanol use induces liver

enzymes,

Cirrhosis is associated with reduced

warfarin metabolism.

Fluvoxamine Probably inhibits warfarin metabolism

(Luvox)

Heparin Has additive anticoagulant effects

HMG CoA May inhibit warfarin metabolism

reductase

inhibitors

Isoniazid May inhibit warfarin metabolism

(Laniazid)

Metronidazole Inhibits metabolism of S enantiomer

(Flagyl) of warfarin

Nalidixic acid Displaces warfarin from protein-binding

(NegGram) sites

Inhibits warfarin metabolism

NSAIDs Inhibit platelet aggregation

Cause gastric erosions

Paroxetine Probably inhibits warfarin metabolism

(Paxil)

Penicillins Dicloxacillin (Pathocil) and nafcillin

(Unipen) may enhance warfarin

metabolism.

Penicillin may reduce gastrointestinal

flora synthesis of vitamin K.

Phenytoin Induces warfarin metabolism

(Dilantin) Displaces warfarin from protein-binding

sites

Enhances metabolism of clotting factors

Propafenone Probably inhibits warfarin metabolism

(Rythmol)

Quinolones Possibly inhibit warfarin metabolism

Rifampin Induce hepatic enzymes

(Rifadin)

and rifabutin Increase warfarin metabolism

(Mycobutin)

Salicylates Inhibit platelet aggregation

Cause gastric erosions

In large doses, result in

hypoprothrombinemic effect

Sulfinpyrazone Inhibits warfarin metabolism

(Anturane)

Thyroid Increases catabolism of vitamin

hormones K-dependent clotting factors

Ticlopidine Inhibits R enantiomer of warfarin

(Ticlid) Inhibits platelet aggregation

Trimethoprim- Sulfonamide component may

sulfamethoxazole stereoselectively inhibit S isomer

(Bactrim) metabolism.

Vitamin E May interfere with production of clotting

factors

Vitamin K Effects of oral anticoagulants are directly

antagonized by the excessive ingestion

of foods or dietary supplements

containing vitamin K.

Drug Management of interaction

Acetaminophen Advise patient to limit total acetaminophen

(Tylenol) dosage to less than 2 g per day; if higher

dosages are used, increased monitoring

may be necessary.

Allopurinol Monitor INR when allopurinol is added or

(Zyloprim) withdrawn.

Amiodarone A 25 percent reduction in the warfarin

(Cordarone) dosage is recommended when amiodarone

is initiated.

Monitor INR closely when amiodarone is

added or withdrawn.

Antifungal Monitor INR when azole antifungals are

agents added or withdrawn.

Antithyroid Monitor INR when antithyroid medications

drugs are added or withdrawn.

Barbiturates Monitor INR when barbiturates are added

or withdrawn; the addition of warfarin

in patients stabilized on a chronic

barbiturate regimen is of less significance.

Binding resins Use colestipol (Colestid), which has a lower

potential for interaction, instead of

cholestyramine (Questran) in patients who

need a bile sequestrant.

Carbamazepine Monitor INR intensively when

(Tegretol) carbamazepine is added or discontinued.

Increase warfarin doses when

carbamazepine is added, and reduce doses

when carbamazepine is discontinued

(stabilization occurs after 4 to 6 weeks).

Cephalosporins Avoid concomitant use of warfarin and

cefoperazone, cefamandole, cefotetan

or cefmetazole.

Cimetidine Use alternative agents in patients receiving

(Tagamet) warfarin.

Monitor INR when concomitant use of

warfarin and cimetidine is necessary.

Contraceptives, If possible, avoid oral contraceptives because

oral of increased risk of thromboembolism

Monitor INR frequently when oral

contraceptives are used concurrently

with warfarin.

Corticosteroids Monitor for gastric toxicity.

Danazol Monitor prothrombin time and INR for 2 days

(Danocrine) to 3 weeks after danazol is added.

Diflunisal If possible, avoid concomitant use of

(Dolobid) warfarin and diflunisal.

Monitor INR if concomitant use is necessary.

Disulfiram If possible, avoid concomitant use of

(Antabuse) warfarin and disulfiram.

Monitor INR if concomitant use is necessary.

Ethanol Caution patients to drink in moderation

and to avoid binge drinking.

Because liver damage results in greater

sensitivity to warfarin, use lower

starting doses.

Fluvoxamine Monitor INR more closely for 1 to 2 weeks

(Luvox) after fluvoxamine is started.

Heparin Heparin may prolong INR, and warfarin

may prolong partial thrombin time.

Be aware of small risk of bleeding events.

HMG CoA Note that lovastatin (Mevacor) is more

reductase commonly associated with

inhibitors hypoprothrombinemia.

Isoniazid Monitor INR when isoniazid is added or

(Laniazid) withdrawn.

Metronidazole Avoid concomitant use of warfarin and

(Flagyl) metronidazole.

Monitor INR if concomitant use is

necessary.

Nalidixic acid Avoid concomitant administration of

(NegGram) warfarin and nalidixic acid.

Monitor INR if concomitant use is

necessary.

NSAIDs Advise patients to avoid NSAIDs or to

use them only intermittently.

Instruct patients to take NSAIDs with

food or antacids.

Consider having patients take misoprostol

(Cytotec) to reduce risk of gastric

erosions.

Paroxetine Monitor INR frequently when paroxetine

(Paxil) is added

Penicillins Monitor INR: dicloxacillin and nafcillin

decrease INR, and penicillin increases

INR.

Phenytoin Monitor INR frequently for 1 month or

(Dilantin) more after phenytoin is added.

Propafenone Monitor INR frequently when

(Rythmol) propafenone is added or discontinued.

Quinolones Monitor INR.

Rifampin Monitor INR closely for 1 to 2 weeks

(Rifadin) after rifampin or rifabutin is added.

and rifabutin

(Mycobutin)

Salicylates If possible, avoid concurrent use of

warfarin and salicylates.

If aspirin is needed, advise patients to

use a small dosage (325 mg or less per

day).

Consider having patients take misoprostol

to reduce the risk of NSAID-induced

ulceration.

Sulfinpyrazone If possible, avoid concomitant use of

(Anturane) warfarin and sulfinpyrazone.

Monitor for bleeding when concomitant

use is necessary.

Thyroid Monitor INR frequently for 1 to 2 months.

hormones

Ticlopidine Monitor for bleeding.

(Ticlid)

Trimethoprim- If possible, avoid concurrent use of

sulfamethoxazole warfarin and trimethoprim-

(Bactrim) sulfamethoxazole.

Monitor INR when concomitant use is

necessary.

Vitamin E Interaction is probably dose-related and

more likely to occur with vitamin E

dosages greater than 800 U per day;

monitor INR if larger dosages are taken.

Vitamin K Advise patients to eat a consistent diet

and to avoid taking large doses of

vitamin supplements containing a great

deal of vitamin K.

INR = International normalized ratio; HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A; NSAIDs = nonsteroidal anti-inflammatory drugs.

Adapted with permission from Havrda DE, Anderson JR, Talbert RL. Thrombosis. In: Pharmacotherapy self assessment program module 1 cardiovascular. Kansas City Mo.: American College of Clinical Pharmacy, 1998. Retrieved September 1998 from the World Wide Web at http:www.accp.com/psap3-des.html. Additional information derived from Warfarin. In: Drugdex. Englewood, Colo.: Micromedex Inc., 1998.

Often, the interacting drugs that pose the greatest problem are those used for short-term indications. Antibiotics are a common example. When interactions occur, close monitoring or the use of alternative antimicrobial agents is appropriate.

Patient Education

Warfarin is more likely to be used safely by a patient who is aware of the potential for drug interactions, understands the rationale for monitoring and can identify the symptoms of warfarin toxicity early. Patient instruction booklets in English and other languages are available from several sources. Du Pont Pharma (1-800-COUMADIN) provides literature for patients, and Barr Laboratories, Inc. (1-888-WARFARIN) has prepared information booklets for both patients and physicians. Most local pharmacies supply similar information to patients.

Final Comment

When used appropriately, warfarin is a highly effective and safe medication. To maximize the safety of warfarin therapy, the physician should do the following:

1. Identify the therapeutic goal.

2. Estimate the chronic maintenance dosage based on the presence of factors associated with hyperresponsiveness or hyporesponsiveness, such as concomitant drug use, liver disease and poor nutrition.

3. Initiate therapy at the patient’s anticipated maintenance dosage. Loading doses are not necessary.

4. Make any necessary adjustments by looking at the cumulative weekly dosage and adding or subtracting 10 to 20 percent evenly over the week.

5. Remain alert to potential warfarin-drug interactions.

Figures 2 and 3 adapted with permission from Norton JL, Gibson DL. Establishing an outpatient anticoagulation clinic in a community hospital. Am J Health Syst Pharm 1996;53:1151-7. Information in Figure 4 from Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(4 Suppl):231S-46S.

REFERENCES

[1.] National prescription audit: physician specialty report, dispensed data. Plymouth Meeting, Pa.: IMS America, 1998.

[2.] Retail perspective and provider perspective audit. Plymouth Meeting, Pa.: IMS America, 1998.

[3.] Agency for Health Care Policy and Research. Life-saving treatments to prevent stroke underused. Press release, September 1995. Retrieved November 1998 from the World Wide Web at http://www.ahcpr.gov/ news/press/stroke.htm.

[4.] Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108(4 Suppl):2315-465.

[5.] Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biologic prosthetic heart valves. Chest 1995;108(4 Suppl):371S-9S [Published erratum in Chest 1996;109:592].

[6.] Levine HJ, Pauker SG, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1995; 108(4 Suppl):360S-705.

[7.] Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336:393-8.

[8.] Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108(4 Suppl):352S-9S.

[9.] Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.

[10.] Majerus PW, Broze GJ, Miletich JP, Tollefsen DM. Anticoagulant thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:1347-51.

[11.] Porter RS, Sawyer WT, Lowenthal DT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. 2d ed. Spokane, Wash.: Applied Therapeutics, 1986:1057-104.

[12.] Harrison L, Johnston M, Massicotte MP, Crowther M, Moffatt K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6.

[13.] Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-4.

[14.] Thomas P, Fennerty A, Backhouse G, Bentley DP, Campbell IA, Routledge PA. Monitoring effects of oral anticoagulants during treatment with heparin. Br Med J [Clin Res] 1984;288:191.

[15.] Ansell JE. Oral anticoagulant therapy–50 years later. Arch Intern Med 1993;153:586-96.

[16.] Carter BL. Therapy of acute thromboembolism with heparin and warfarin. Clin Pharm 1991;10: 503-18.

[17.] Norton JL, Gibson DL. Establishing an outpatient anticoagulation clinic in a community hospital. Am J Health Syst Pharm 1996;53:1151-7.

[18.] Wittkowsky AK. Generic warfarin: implications for patient care [Editorial]. Pharmacotherapy 1997;17: 640-3.

[19.] Richton-Hewett S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988;148:806-8.

[20.] Routledge PA, Chapman DH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol 1979; 8:243-7.

[21.] Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108(4 Suppl):276S-90S.

[22.] Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-28.

[23.] Landefeld CS, Rosenblatt MW, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52.

[24.] Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994;154:1443-8.

[25.] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57 [Published erratum in Arch Intern Med 1994;10:2254].

[26.] Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of. chronic anticoagulation: a multicenter study. Ann Intern Med 1993;118:511-20.

[27.] Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991;229:351-5.

[28.] Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-9.

[29.] Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.

[30.] Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.

[31.] Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633-8.

[32.] Havrda DE, Anderson JR, Talbert RL. Thrombosis. In: Pharmacotherapy self assessment program module 1 cardiovascular. Kansas City, Mo.: American College of Clinical Pharmacy; 1998. Retrieved September 1998 from the World Wide Web at http:www.accp.com/psap3-des.html.

[33.] Warfarin. In: Drugdex. Englewood, Colo.: Micromedex Inc., 1998.

JON D. HORTON, PHARM.D., is pharmacy director of the anticoagulation therapy service and a practicing clinical pharmacist at York (Pa.) Hospital. He also serves as clinical assistant professor at the University of Maryland School of Pharmacy, Baltimore. Dr. Horton graduated from the University of Pittsburgh School of Pharmacy and earned his doctor of pharmacy degree from Duquesne University, Pittsburgh.

BRUCE M. BUSHWICK, M.D., is associate program director for the family practice residency program at York Hospital and clinical assistant professor of family and community medicine at the Milton S. Hershey Medical Center, Pennsylvania State University, Hershey. Dr. Bushwick graduated from the University of Maryland School of Medicine, Baltimore, and completed a family practice residency at York Hospital.

Address correspondence to Jon D. Horton, Pharm. D, Department of Pharmacy, York Hospital, 1001 S. George St., York, PA 17405. Reprints are not available from the authors.

Richard W. Sloan, M.D., R. PH., coordinator of this series, is chairman and residency program director of the Department of Family Medicine at York (Pa.) Hospital and clinical associate professor in family and community medicine at the Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pa.

COPYRIGHT 1999 American Academy of Family Physicians

COPYRIGHT 2008 Gale, Cengage Learning